PE20100052A1 - 3-OXOISOINDOLIN-1-CARBOXAMIDE DERIVATIVES AS INHIBITORS OF SODIUM CHANNELS - Google Patents

3-OXOISOINDOLIN-1-CARBOXAMIDE DERIVATIVES AS INHIBITORS OF SODIUM CHANNELS

Info

Publication number
PE20100052A1
PE20100052A1 PE2009000757A PE2009000757A PE20100052A1 PE 20100052 A1 PE20100052 A1 PE 20100052A1 PE 2009000757 A PE2009000757 A PE 2009000757A PE 2009000757 A PE2009000757 A PE 2009000757A PE 20100052 A1 PE20100052 A1 PE 20100052A1
Authority
PE
Peru
Prior art keywords
carboxamide
oxoisoindolin
inhibitors
oxo
methyl
Prior art date
Application number
PE2009000757A
Other languages
Spanish (es)
Inventor
Yevgeni Besidski
Alf Claesson
Istvan Macsari
Gabor Csjernyik
Linda I Nilsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20100052A1 publication Critical patent/PE20100052A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 3-OXOISOINDOLIN-1-CARBOXAMIDA DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C3), ALCOXI(C1-C3), CN, ENTRE OTROS; m ES 1 O 2; R2 Y R3 SON CADA UNO H, HALOALQUILO(C1-C4), HALOALCOXI(C1-C4), HALO, ENTRE OTROS; D ES CICLOALQUILO(C3-C7) O HETEROCICLOALQUILO(C3-C7); L1 ES ALQUILENO(C1-C4) O UN ENLACE; L2 ES ALQUILENO(C1-C3). SON COMPUESTOS PREFERIDOS: 2-(OXAN-4-IL)-3-OXO-N-[[4-(TRIFLUOROMETOXI)FENIL]METIL]-1H-ISOINDOL-1-CARBOXAMIDA, 2-(4,4-DIFLUOROCICLOHEXIL)-3-OXO-N-[4-(TRIFLUOROMETOXI)BENCIL]ISOINDOLIN-1-CARBOXAMIDA, 3-OXO-2-[[(2S)-OXOLAN-2-IL]METIL]-N-[[4-(TRIFLUOROMETOXI)FENIL]METIL]-1H-ISOINDOL-1-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LOS CANALES DE SODIO NaV1,7 SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR AGUDO, DOLOR CRONICO, DOLOR NEUROPATICO, LUMBALGIAREFERS TO COMPOUNDS DERIVED FROM 3-OXOISOINDOLIN-1-CARBOXAMIDE OF FORMULA (I) WHERE R1 IS H, ALKYL (C1-C3), ALCOXY (C1-C3), CN, AMONG OTHERS; m IS 1 O 2; R2 AND R3 ARE EACH H, HALOALKYL (C1-C4), HALOALCOXY (C1-C4), HALO, AMONG OTHERS; D IS CYCLOALKYL (C3-C7) OR HETERO CYCLOALKYL (C3-C7); L1 IS ALKYLENE (C1-C4) OR A LINK; L2 IS ALKYLENE (C1-C3). PREFERRED COMPOUNDS ARE: 2- (OXAN-4-IL) -3-OXO-N - [[4- (TRIFLUOROMETOXY) PHENYL] METHYL] -1H-ISOINDOL-1-CARBOXAMIDE, 2- (4,4-DIFLUOROCYCLOHEXYL) - 3-OXO-N- [4- (TRIFLUOROMETOXI) BENZYL] ISOINDOLIN-1-CARBOXAMIDE, 3-OXO-2 - [[(2S) -OXOLAN-2-IL] METHYL] -N - [[4- (TRIFLUOROMETOXI) PHENYL] METHYL] -1H-ISOINDOL-1-CARBOXAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF NaV1,7 SODIUM CHANNELS, BEING USEFUL IN THE TREATMENT OF ACUTE PAIN, CHRONIC PAIN, NEUROPATHIC PAIN, LOW BACK

PE2009000757A 2008-05-30 2009-05-29 3-OXOISOINDOLIN-1-CARBOXAMIDE DERIVATIVES AS INHIBITORS OF SODIUM CHANNELS PE20100052A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5731008P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
PE20100052A1 true PE20100052A1 (en) 2010-02-20

Family

ID=41377346

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000757A PE20100052A1 (en) 2008-05-30 2009-05-29 3-OXOISOINDOLIN-1-CARBOXAMIDE DERIVATIVES AS INHIBITORS OF SODIUM CHANNELS

Country Status (6)

Country Link
AR (1) AR071954A1 (en)
CL (1) CL2009001328A1 (en)
PE (1) PE20100052A1 (en)
TW (1) TW201000446A (en)
UY (1) UY31854A (en)
WO (1) WO2009145721A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (en) 2010-10-07 2015-08-10 Common Crystals and Salts of CCR3 Inhibitors
MX2013004307A (en) 2010-10-18 2013-07-17 Raqualia Pharma Inc Arylamide derivatives as ttx-s blockers.
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2018110669A1 (en) * 2016-12-15 2018-06-21 Ono Pharmaceutical Co., Ltd. Activator of trek (twik related k+ channels) channels
CA3108792A1 (en) 2018-09-10 2020-03-19 Kaken Pharmaceutical Co., Ltd. Novel heteroaromatic amide derivative and medicament containing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
GB0514017D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
EP2044019A1 (en) * 2006-07-12 2009-04-08 Astra Zeneca AB 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
TW201000446A (en) 2010-01-01
UY31854A (en) 2010-01-05
AR071954A1 (en) 2010-07-28
CL2009001328A1 (en) 2010-01-15
WO2009145721A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
PE20120008A1 (en) DERIVATIVES OF PHENOXY BENZENOSULFONAMIDE
PE20100052A1 (en) 3-OXOISOINDOLIN-1-CARBOXAMIDE DERIVATIVES AS INHIBITORS OF SODIUM CHANNELS
PE20091201A1 (en) AMIDES SUBSTITUTED AS INHIBITORS OF BRUTON TYROSINE KINASE (Btk)
PE20080951A1 (en) DERIVATIVES OF 2-OXO-ETHYL-AMINO-PROPIONAMIDE-PYRROLIDIN-2-IL-SUBSTITUTED AS INHIBITORS OF THE BINDING OF THE PROTEIN Smac TO THE INHIBITOR OF THE PROTEIN OF APOPTOSIS
PE20131377A1 (en) TRIAZINE-OXADIAZOLES
PE20081353A1 (en) PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS
AR104566A2 (en) CRYSTAL FORM OF SALT DICHLORHYDRATE OF ((1S) -1 - (((2S) -2- (5- (4- (2 - ((2S) -1 - ((2S) -2 - ((METOXICARBONIL) AMINO ) -3-METHYLBUTANOIL) -2-PIRROLIDINIL) -1H-IMIDAZOL-5-IL) -4-BIFENILIL) -1H-IMIDAZOL-2-IL) -1-PIRROLIDINIL) CARBONIL) -2-METHYLPROPIL) METHYL CARBAMATE
PE20090816A1 (en) PYRROLOPYRIMIDINONE DERIVATIVES AS BINDING AGENTS OF P2X3 RECEPTORS
PE20081845A1 (en) NEW AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS
PE20090641A1 (en) HETERO CYCLIC AMIDES
PE20141825A1 (en) TETRAHYDROISOQUINOLINE COMPOUNDS SUBSTITUTED AS INHIBITORS OF THE XIA FACTOR
PE20140913A1 (en) NAMPT AND ROCK INHIBITORS
PE20090649A1 (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF THE ENZYME 11ßHSD1
PE20121157A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SERINE PROTEASES
PE20140690A1 (en) BENZOXAZEPINONES FUSED AS ION CHANNEL MODULATORS
PE20091952A1 (en) TIAZOLE AND OXAZOLE COMPOUNDS OF BENZENE SULFONAMIDE
PE20121010A1 (en) BENZIMIDAZOLE DERIVATIVES
PE20090601A1 (en) PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS
PE20091002A1 (en) DIPEPTIDED ANALOGS AS INHIBITORS OF THE COAGULATION FACTOR
PE20091656A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAF KINASE
PE20080404A1 (en) BENZYL-AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS
PE20081836A1 (en) PIPERIDINE DERIVATIVES AS INHIBITORS OF FATTY ACID SYNTHASE
PE20091842A1 (en) PYRROLIDINONES AS GLUCOKINASE ACTIVATORS
PE20090549A1 (en) IMIDAZOLIDINONE DERIVATIVES WITH ACTIVITY ON LXR-ALPHA AND LXR-BETA
PE20110433A1 (en) ANTAGONISTS OF THE DISUSTITUTED PHTHALAZINE HEDGEHOG PATHWAY

Legal Events

Date Code Title Description
FA Abandonment or withdrawal